Risk factors for mortality in Acinetobacter calcoaceticus-baumannii bacteraemia

Asian Pacific Journal of Tropical Biomedicine

Volumn 2, Issue 3 SUPPL., 2012, Pages

  Mehta, Asmita A ^a   Kumar, V Anil ^a   Kumari, Indira K ^a   Nair, Suresh G ^a   Dinesh, Kavitha R ^a   Singh, Sanjeev K ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acinetobacter calcoaceticus baumannii; Blood culture; Colonization; Diabetes mellitus; End stage renal disease; Mechanical ventilation

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; CEFOPERAZONE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; CREATININE; GENTAMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; UREA;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTION; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; BODILY SECRETIONS; CEREBROVASCULAR ACCIDENT; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DISK DIFFUSION; FEMALE; HEART FAILURE; HUMAN; INDIA; INFANT; INFECTION RISK; INTRAVASCULAR CATHETER; KIDNEY FAILURE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; MULTIDRUG RESISTANCE; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK ASSESSMENT; THROMBOCYTE COUNT; UREA BLOOD LEVEL;

ACINETOBACTER CALCOACETICUS;

EID: 84875388497     PISSN: 22211691     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2221-1691(12)60507-3     Document Type: Article

References (30)

1. Prashanth K, Badrinath S Nosocomial infections due to Acinetobacter species: Clinical findings, risk and prognostic factors. Indian J Med Microbiol 2006, 24:39-44.
2. Cisneros J, Rodríguez-Baño J, Fernández-Cuenca F, Ribera A, Vila J, Pascual A, et al. Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect 2005, 11:874-879.
3. Baran G, Erbay A, Bodur H, öngürü P, AkIncI E, Balaban N, et al. Risk factors for nosocomial imipenem-resistant Acinetobacter Baumanni infections. Int J Infect Dis 2008, 12:16-21.
4. Jung J, Park MS, Kim SE, Park BH, Son JY, Kim EY, et al. Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect DiS 2010, 10:228.
5. Joshi S, Litake GM, Satpute MG, Telang NV, Ghole VS, et al. Clinical and demographic features of infection caused by Acinetobacter species. Indian J Med Sci 2006, 60:351-360.
6. Talbot G, Bradley J, Edwards JJ, Gilbert D, Scheld M, Bartlett JG Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of america. Clin Infect Dis 2006, 42:657-668.
7. Allen D, Hartman BJ Acinetobacter species. Principles and practice of infectious diseases 2000, 2339-2344. Churchill Livingstone, Philadelphia. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
8. Maragakis L, Perl TM Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008, 46:1254-1263.
9. Falagas M, Bliziotis IA, Siempos I Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Critical care 2006, 10:48.
10. American Thoracic Society documents Guidelines for the management of adults with hospital acquired pneumonia, ventilator associated pneumonia and health care associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
11. Garner J, Jarvis WR, Emori TG, Horan TC, Hughes JM CDC definitions of nosocomial infections. APIC Infection Control and Applied Epidemiology: Principles and Practice 1996, A-1-A-20. Mosby, St. Louis. R.N. Olmsted (Ed.).
12. Document of Public welfare department of health and human services United States of America Code of federal regulations http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html#46.101.
13. Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptiblity Tests for Bacteria That Grow Aerobically; Approved Standard-8th Edition. Clinical and Laboratory Standards Institute 2008, 29:M07-A08.
14. Kwon K, Oh WS, Song J, Chang H, Jung S, Kim S, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrobiol Chemother 2007, 59:525-530.
15. Yu Y, Yang Q, Xu XW, Kong HS, Xu GY, Zhong BY Typing and characterization of carbapenem-resistant Acinetobacter calcoaceticus-baumannii complex in a Chinese hospital. J Med Microbiol 2004, 53:653-656.
16. Luna C, Aruj PK Nosocomial Acinetobacter Pneumonia. Respirology 2007, 12:787-797.
17. Cisneros-Herreros JM, Garnacho-Montero J, Pachon Ibanez ME Nosocomial Pneumonia due to Acinetobacter baumannii. Enferem Infecc Microbiol Clin 2005, 23:46-51.
18. Robenshtok E, Paul M, Leibovici L, Fraser A, Pitlik S, Ostfeld I, et al. The significance of Acinetobacter baumanni bacteremia compared with Klebsiella Pneumoniae bacteremia: Risk factors and outcomes. J Hosp Infect 2006, 64:282-287.
19. Jang T, Lee SH, Huang CH, Lee CL, Chen WY Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect 2009, 73:143-150.
20. Shih M, Lee N, Lee H, Chang C, Wu C, Chen P, et al. Risk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case-control study. Journal of Microbiology. Immunol Infect 2008, 41:118-123.
21. Corbella X, Montero A, Pujol M, Domnguez MA, Ayats J, Argerich MJ, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clinical Microbiol 2000, 38:4086-4095.
22. Chen H, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, et al. Predictors of mortality in Acinetobacter baumanni bacteremia. Microbiol Immunol Infect 2005, 38:127-136.
23. Zakuan Z, Mohd NS, Harun A Risk factors and outcomes of imipenem-resistant Acinetobacter blood stream infection in North-eastern Malaysia. Asian Pacific J Trop Biomed 2011, 1:313-315.
24. Erbay A, Idil A, Gözel MG, Mumcuoglu I, Balaban N Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009, 34:575-579.
25. Kumarasamy K, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
26. Lahiri K, Mani NS, Purai SS Acinetobacter spp. as nosocomial pathogens: Clinical significance and antimicrobial sensitivity. Med J Armed Forces India 2004, 60:7-10.
27. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 2009, 30:1186-1192.
28. Falagas M, Bliziotis IA, Siempos I Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Critical Care 2006, 10(2):R48-R49.
29. Erbay A, Idil A, Gzel MG, Mumcuoĝlu I, Balaban N Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009, 34(6):575-579.
30. Metan G, Sariguzel F, Sumerkan B Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. European J Int Med 2009, 20(5):540-544.